focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCavendish Fin Regulatory News (CAV)

Share Price Information for Cavendish Fin (CAV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11.50
Bid: 11.00
Ask: 12.00
Change: 0.00 (0.00%)
Spread: 1.00 (9.091%)
Open: 11.50
High: 11.50
Low: 11.50
Prev. Close: 11.50
CAV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

4 Apr 2024 07:00

RNS Number : 2115J
Cavendish Financial PLC
04 April 2024
 

4 April 2024

Cavendish Financial plc ("Cavendish")

Trading update(1) - strong post-merger performance

Cavendish (LON: CAV), a leading UK mid-market investment bank, today issues a trading update for the year ended 31 March 2024.

Financial performance(1)

In H2, we saw significant growth with revenues expected to be approximately £34.5m, c.77% up on pro forma H1 revenue of £19.5m. As a result, statutory revenue for the full year is expected to be approximately £47.5m (FY23: £32.9m) up c.44%. On a full year pro forma basis revenue is expected to be c.£54m (FY23 pro forma: £50.5m).

The newly merged team delivered an H2 performance well ahead of H1 as we completed multiple deals for our clients, across all parts of our business and strengthened our balance sheet further. As at 31 March 2024, cash was approximately £20.8m, up from c.£12.3m at our half year.

Having locked in annualised synergies of £7m, we continue to deliver further savings from the merger and the run rate cost base of the merged group has been substantially reduced giving us greater resilience and better operating leverage.

Outlook

Whilst the interest rate cycle appears to have peaked, conditions continue to impact demand for UK equities, making deal execution in ECM challenging across all market participants. However, private and public M&A has remained buoyant in H2 and our pipeline across both ECM and M&A remains good.

The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Cavendish's obligations under Article 17 of the UK MAR. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

CONTACTS

Cavendish (Management) Tel: +44 (0) 207 220 0500

Julian Morse, Co-Chief Executive Officer

John Farrugia, Co-Chief Executive Officer

Ben Procter, Chief Financial Officer

Grant Thornton (Nominated Adviser) Tel: +44 (0) 207 383 5100

Philip Secrett/Samantha Harrison

Cavendish (Broker) Tel: +44 (0) 207 220 0500

Tim Redfern

Hudson Sandler (PR) Tel: +44 (0) 20 7796 4133

Dan de Belder/Rebekah Chapman

(1) References to unaudited pro forma revenues reflect the addition of the unaudited consolidated revenue of finnCap Group plc and the unaudited consolidated revenue of Cenkos Securities plc for the relevant period as if they were consolidated fully for that period. Pro forma information is a non-GAAP measure and is provided to assist with a better understanding of Cavendish's performance.

 

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSSMFLDELSELL
Date   Source Headline
22nd Apr 202410:00 amRNSDirectors Dealings
8th Apr 20247:01 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSChange of Nominated Adviser
4th Apr 20247:00 amRNSTrading Update
28th Mar 20247:00 amRNSTotal Voting Rights
19th Mar 20242:26 pmRNSDirectors Dealings and Total Voting Rights
29th Feb 20247:00 amRNSTotal Voting Rights
20th Feb 20247:00 amRNSTotal Voting Rights and Directors Dealings
19th Feb 20247:00 amRNSLaunch of SIP and Co-investment Plan
19th Jan 20247:00 amRNSHolding(s) in Company
20th Dec 202310:19 amRNSIncoming Director Dealing
19th Dec 202311:11 amRNSDirector Dealings
19th Dec 20237:00 amRNSBoard Changes
19th Dec 20237:00 amRNS2024 Interim Results
1st Dec 20237:00 amRNSBlock Admission Return and Total Voting Rights
29th Sep 202310:44 amRNSResult of AGM
29th Sep 20237:00 amRNSAGM Trading Statement
19th Apr 20056:24 pmRNSOffer Update
12th Apr 20053:13 pmRNSAGM Statement
5th Apr 20057:01 amRNSOffer Update/Directorate
2nd Mar 200510:54 amRNSOffer Update
1st Mar 20051:16 pmRNSOffer Update
21st Feb 20057:00 amRNSOffer Update
31st Jan 20059:26 amRNSOffer Document Posted
28th Jan 20055:47 pmRNSDividend Declaration
28th Jan 20054:34 pmRNSOffer by Chrysalis VCT plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.